OBJECTIVE
To assess the impact of certolizumab pegol (CZP), a novel PEGylated anti-tumor necrosis factor, in combination with methotrexate (MTX) on productivity outside and within the home, and on participation in family, social, and leisure activities in adult patients with rheumatoid arthritis (RA).
METHODS
The efficacy and safety of CZP (200 mg and 400 mg) plus MTX were assessed in 2 phase...